The FDA has approved Amgen's Xgeva for treatment of a rare, usually nonmalignant tumor of the bone. The drug was first approved to protect against fractures when cancer metastasizes to bone.
Published in Brief:
|Vice President of Finance||
Urban Health Plan, Inc.
|Director of Payor/Provider Contracting||
U.S. Medical Management
|Director, Corporate Counsel - Regulatory Law||
|ISHN - Chief Compliance Officer||
Mountain States Health Alliance
|Johnson City, TN|
|Consumer Directed Health Plan (CDH) Product Offering Manager||
Blue Cross Blue Shield MA